VBI-1901: AACR Data and Clinical Update in Recurrent GBM

June 22, 2020 | Video

David E. Anderson, Ph.D., discusses updated Part B data from the VBI's ongoing Phase 1/2a study of VBI-1901, the company’s cancer vaccine immunotherapeutic, with Allen Waziri, M.D., CEO and Co-Founder, iCE Neurosystems, Former Director of the Brain Tumor Program at Inova Neuroscience Institute, and member of VBI’s GBM/Immuno-Oncology Scientific and Clinical Advisory Board.

View More Videos

  • VBI-1901: Phase 2a Data & Clinical Update in Recurrent GBM

    Discussion of Data Presented at Society for Neuro-Oncology (SNO) 2020 Annual Meeting

    Watch NowArrow
  • Overview of First- and Second-Generation Hepatitis B Vaccines

  • Overview of the Design of VBI-1901, VBI’s Therapeutic Cancer Vaccine Candidate

  • Preclinical Data from VBI-1901, VBI’s Therapeutic Cancer Vaccine Candidate

  • About Medulloblastoma

  • About Glioblastoma (GBM)

  • About Hepatitis B (HBV)

  • Overview of VBI-1501, VBI’s Cytomegalovirus (CMV) Vaccine Candidate

  • Overview of VBI’s Enveloped Virus-Like Particle (eVLP) Platform Technology


Sign-up for Our Distribution List to Receive the Latest News and Updates from VBI

Sign Up NowArrow
Go top